bluebird bio Inc. (BLUE)

139.86
1.74 1.26
NASDAQ : Health Technology
Prev Close 138.12
Open 138.72
Day Low/High 138.51 / 141.80
52 Wk Low/High 87.49 / 181.45
Volume 534.08K
Avg Volume 538.60K
Exchange NASDAQ
Shares Outstanding 55.12M
Market Cap 7.79B
EPS -10.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio Announces Live Webcast Of EHA Data Review And ZYNTEGLO® (autologous CD34 Cells Encoding βA-T87Q-globin Gene) Approval

Bluebird Bio Announces Live Webcast Of EHA Data Review And ZYNTEGLO® (autologous CD34 Cells Encoding βA-T87Q-globin Gene) Approval

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting, and to discuss the approval of ZYNTEGLO ® (autologous CD34+ cells...

Bluebird Bio Announces EU Conditional Marketing Authorization For ZYNTEGLO™ (autologous CD34 Cells Encoding βA-T87Q-globin Gene) Gene Therapy For Patients 12 Years And Older With Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

Bluebird Bio Announces EU Conditional Marketing Authorization For ZYNTEGLO™ (autologous CD34 Cells Encoding βA-T87Q-globin Gene) Gene Therapy For Patients 12 Years And Older With Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype

bluebird bio, Inc . (Nasdaq: BLUE) announced today that the European Commission (EC) has granted conditional marketing authorization for ZYNTEGLO™ (autologous CD34+ cells encoding β A-T87Q-globin gene), a gene therapy for patients 12 years and older with...

Bluebird Bio Announces Investor Events In June

Bluebird Bio Announces Investor Events In June

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company will hold a conference call to discuss data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 14 at 8:00 am ET.

CVS, Lowe's, Micron: 'Mad Money' Lightning Round

CVS, Lowe's, Micron: 'Mad Money' Lightning Round

A rundown of Cramer's takes on stocks of interest to Mad Money viewers.

It's Getting Emotional: Cramer's 'Mad Money' Recap (Wednesday 5/29/19)

It's Getting Emotional: Cramer's 'Mad Money' Recap (Wednesday 5/29/19)

The current selloff is finally starting to prompt overwrought responses from investors, Jim Cramer says.

Bluebird Bio To Present New Data From Clinical Studies Of LentiGlobin™ Gene Therapy For Transfusion-Dependent β-thalassemia (TDT) And LentiGlobin Gene Therapy For Sickle Cell Disease (SCD) At The 24th EHA Congress

Bluebird Bio To Present New Data From Clinical Studies Of LentiGlobin™ Gene Therapy For Transfusion-Dependent β-thalassemia (TDT) And LentiGlobin Gene Therapy For Sickle Cell Disease (SCD) At The 24th EHA Congress

bluebird bio, Inc. (Nasdaq: BLUE) announced today that new data from its investigational gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) will be presented during the 24th European Hematology Association...

Bluebird Bio's Analyst Day Highlights Commercial Path To Patients And Research Engine Focused On Next-Generation Gene And Cell Therapies

Bluebird Bio's Analyst Day Highlights Commercial Path To Patients And Research Engine Focused On Next-Generation Gene And Cell Therapies

bluebird bio, Inc. (Nasdaq: BLUE) today will host an Analyst Day in New York that will highlight significant progress in the company's emerging immuno-oncology and severe genetic disease pipeline, provide updates on launch expectations for its first gene...

Bluebird Bio Announces Investor Events In May

Bluebird Bio Announces Investor Events In May

bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company will host an Analyst Day, Thursday, May 9, at 8:30 am ET at The Maxwell Hotel NYC, New York, NY.

Bluebird Bio Reports First Quarter 2019 Financial Results And Highlights Operational Progress

Bluebird Bio Reports First Quarter 2019 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2019.

Celgene Corporation And Bluebird Bio Announce Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Multiple Myeloma Published In New England Journal Of Medicine

Celgene Corporation And Bluebird Bio Announce Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Multiple Myeloma Published In New England Journal Of Medicine

Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies' lead investigational...

Bluebird Bio Appoints Joanne Smith-Farrell, Ph.D., To Chief Business Officer

Bluebird Bio Appoints Joanne Smith-Farrell, Ph.D., To Chief Business Officer

bluebird bio, Inc. (Nasdaq: BLUE), has appointed Joanne Smith-Farrell, Ph.

What Can't Amazon Do?: Cramer's 'Mad Money' Recap (Monday 4/15/19)

What Can't Amazon Do?: Cramer's 'Mad Money' Recap (Monday 4/15/19)

Amazon seems nearly unstoppable, says Jim Cramer. So be careful if you own something that could be in the retail giant's crosshairs.

Bluebird Bio Receives Positive Opinion From CHMP For ZYNTEGLO™ (autologous CD34 Cells Encoding βA-T87Q-globin Gene) Gene Therapy For Patients 12 Years And Older With Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

Bluebird Bio Receives Positive Opinion From CHMP For ZYNTEGLO™ (autologous CD34 Cells Encoding βA-T87Q-globin Gene) Gene Therapy For Patients 12 Years And Older With Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

bluebird bio, Inc. (Nasdaq:BLUE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending conditional marketing authorization for ZYNTEGLO™ (autologous...

Bluebird Bio Opens State-of-the-Art Gene And Cell Therapy Manufacturing Facility In Durham, North Carolina

Bluebird Bio Opens State-of-the-Art Gene And Cell Therapy Manufacturing Facility In Durham, North Carolina

bluebird bio, Inc. (Nasdaq: BLUE) today announced the official opening of its first wholly owned manufacturing facility in Durham, N.

Bluebird Bio To Present At Investor Conferences In March

Bluebird Bio To Present At Investor Conferences In March

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Cowen and Company 39 th Annual Health Care Conference, Tuesday, March 12, at 8:40 am ET at the Boston...

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Bluebird Bio Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Operational Progress

Bluebird Bio Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.

Bluebird Bio Appoints Chip Baird As Chief Financial Officer

Bluebird Bio Appoints Chip Baird As Chief Financial Officer

bluebird bio, Inc. (Nasdaq:BLUE) announced Chip Baird will join the company effective today and assume the role of chief financial officer (CFO).

Bluebird Bio And Inhibrx Announce Collaboration To Research, Develop And Commercialize CAR T Cell Immunotherapies

Bluebird Bio And Inhibrx Announce Collaboration To Research, Develop And Commercialize CAR T Cell Immunotherapies

bluebird bio, Inc. (Nasdaq: BLUE) and Inhibrx, Inc.

Bluebird Bio To Present At The 37th Annual J.P. Morgan Healthcare Conference

Bluebird Bio To Present At The 37th Annual J.P. Morgan Healthcare Conference

bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 37 th Annual J.

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Bluebird Bio, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Bluebird Bio, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Bluebird Bio, Inc. - BLUE

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Bluebird Bio, Inc. - BLUE

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of bluebird bio, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Bluebird Bio, Inc. Investors (BLUE)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Bluebird Bio, Inc. Investors (BLUE)

Law Offices of Howard G. Smith announces an investigation on behalf of Bluebird Bio, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Bluebird Bio, Inc. Investors (BLUE)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Bluebird Bio, Inc. Investors (BLUE)

Law Offices of Howard G. Smith announces an investigation on behalf of Bluebird Bio, Inc.

Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Sickle Cell Disease At 60th Annual Meeting Of The American Society Of Hematology

Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Sickle Cell Disease At 60th Annual Meeting Of The American Society Of Hematology

bluebird bio, Inc. (Nasdaq: BLUE) announced new data from patients in Group C of its ongoing Phase 1/2 HGB-206 study of the company's investigational LentiGlobin ™ gene therapy in patients with sickle cell disease (SCD) today at the 60 th Annual Meeting...

Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Transfusion Dependent β-Thalassemia At 60th Annual Meeting Of The American Society Of Hematology

Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Transfusion Dependent β-Thalassemia At 60th Annual Meeting Of The American Society Of Hematology

bluebird bio, Inc. (Nasdaq: BLUE) announced new data from the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) clinical studies of its investigational LentiGlobin ™ gene therapy in the treatment of patients with transfusion-dependent β-thalassemia...

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

Bluebird Bio And Celgene Corporation Present Initial Data From Ongoing Phase 1 Clinical Study Of Next-Generation Anti-BCMA CAR T Cell Therapy Bb21217 In Patients With Relapsed/Refractory Multiple Myeloma At ASH Annual Meeting

bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with...

Bluebird Bio Presents Updated Data From Clinical Studies Of LentiGlobin Gene Therapy In Transfusion-Dependent β-Thalassemia And Sickle Cell Disease At 60th Annual Meeting Of The American Society Of Hematology

Bluebird Bio Presents Updated Data From Clinical Studies Of LentiGlobin Gene Therapy In Transfusion-Dependent β-Thalassemia And Sickle Cell Disease At 60th Annual Meeting Of The American Society Of Hematology

bluebird bio, Inc. (Nasdaq: BLUE) announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin ™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2...

TheStreet Quant Rating: D (Sell)